Immunohistochemistry or IHC
NR4A3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid/microcystic morphology
Genes, Chromosomes, and Cancer 2022 December 16 [Link] Abbas Agaimy, Luka Brcic, Laurence M Briski, Yin P Hung, Michael Michal, Michal Michal, G Petur Nielsen, Robert Stoehr, Andrew E Rosenberg Abstract A focal adenomatoid-microcystic pattern is not uncommon in peritoneal mesothelioma, but tumors composed almost exclusively of this pattern are distinctly rare and have not…
Read MoreUsefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study
Lung Cancer 2022 November 19 [Link] Prakasit Sa-Ngiamwibool, Makoto Hamasaki, Yoshiaki Kinoshita, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Kunimitsu Kawahara, Takahiko Kasai, Kei Kushitani, Yukio Takeshima, Kenzo Hiroshima, Akinori Iwasaki, Kazuki Nabeshima Abstract Objectives: BAP1, CDKN2A, and NF2 are the most frequently altered genes in pleural mesotheliomas (PM). Discriminating PM from benign mesothelial proliferation (BMP)…
Read MoreHistopathological and immunohistochemical features of 14 peritoneal mesotheliomas with clinical outcomes and recent updates
Journal of Cancer Research and Therapeutics 2022 Oct-Dec [Link] Srushti Karmarkar, Bharat Rekhi, Kedar K Deodhar, Santosh Menon Abstract Background: Malignant peritoneal mesotheliomas (MPMs) are rare tumors with overlapping clinical and histopathological features, especially with epithelial ovarian carcinomas (EOCs). There is no substantial documentation on these rare tumors from our country. Objective: To study the…
Read MoreRhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma
Scientific Reports 2022 November 2 [Link] Takuya Hiratsuka, Takushi Yamamoto, Akihiko Yoshizawa, Shinya Toyokuni, Tatsuaki Tsuruyama Abstract Diagnostic markers of malignant mesothelioma (MM) have been extensively investigated. Immunohistochemistry (IHC) markers, such as calretinin, have been used for pathologic diagnosis. However, more diagnostic markers are required to improve the specificity and sensitivity of pathologic diagnosis. This…
Read MoreLoss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases
World Journal of Surgical Oncology 2022 October 24 [Link] He-Liang Wu, Zhi-Ran Yang, Yan-Dong Su, Ru Ma, Xue-Mei Du, Ying Gao, Yan Li Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with a high mortality rate and extremely poor prognosis. In-depth pathological analysis is essential to assess tumor biological behaviors and explore…
Read MoreCytological Diagnosis of Malignant Mesothelioma: A Case Series
Journal of Cytology 2022 July-September [Link] Sakshi Dahiya, Meeta Singh, Shyama Jain, Bembem Khuraijam, Naman Suroya, Shramana Mandal Abstract Background: Mesotheliomas are neoplasms of the serosal lining of the body cavities. Diagnosis requires a multimodal approach of clinical findings, cytology, and histopathology with immunohistochemistry (IHC). The published sensitivity of cytology for diagnosing mesothelioma ranges from…
Read MoreNew candidates in the differential diagnosis of malignant mesothelioma from benign mesothelial hyperplasia and adenocarcinoma; DARS2 and suprabasin
Tissue & Cell 2022 September 6 [Link] Ozlem Ucer, Nevin Kocaman Abstract Objectives: Malignant mesothelioma (MM) is a primary malignant tumour with a very bad prognosis, which develops from the mesothelial cells lining the serosal surfaces. Because MM can show a wide variety of histological patterns and its cytomorphological features are quite extensive, it is…
Read MoreInvestigation of pd-l1 (cd274), pd-l2 (pdcd1lg2), and ctla-4 expressions in malignant pleural mesothelioma by immunohistochemistry and real-time polymerase chain reaction methods
Polish Journal of Pathology 2022 October 6 [Link] Fatma Sule Kutlar Dursun, Ulas Alabalik Abstract Introduction: Malignant pleural mesothelioma (MPM) is an aggressive malignant disease with a poor prognosis, which affects the surface mesothelium of the pleural cavity. Immune checkpoints are responsible for controlling the immune system to avoid autoimmunity and prevent tissue damage. In…
Read MoreEffects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy
Cancer Immunology, Immunotherapy 2022 September 17 [Link] Riki Okita, Yuka Mimura-Kimura, Nobutaka Kawamoto, Naoki Yamamoto, Masashi Umeda, Masanori Okada, Hidetoshi Inokawa, Yusuke Mimura, Tomoyuki Murakami, Masao Nakata, Kazunori Okabe Abstract Programmed cell death protein-1 (PD1), PD1 ligand 1 (PD-L1), and human leukocyte antigen (HLA) class I molecule play pivotal roles in T cell-induced anti-tumor immunity;…
Read MoreBrief Report: Multimodality Therapy in Patients with Primary Pericardial Mesothelioma
Journal of Thoracic Oncology 2022 September 5 [Link] Michael Offin, Dilanka De Silva, Jennifer L Sauter, Jacklynn V Egger, Ellen Yorke, Prasad S Adusumilli, Andreas Rimner, Valerie W Rusch, Marjorie G Zauderer Abstract Background: Primary pericardial mesothelioma (PPM) has no accepted standard of care treatment options with management and outcomes often extrapolated from diffuse pleural…
Read More